Want to see BRTX full AI Analyst Report?
BRTX Stock Chart & Stats
$1.18
-$0.13(-7.22%)
At close: 4:00 PM EST
$1.18
-$0.13(-7.22%)
Day’s Range― - ―
52-Week Range$0.16 - $1.89
Previous CloseN/A
Volume34.37K
Average Volume (3M)20.75M
Market Cap
$10.19M
Enterprise Value$514.34K
Total Cash (Recent Filing)$3.59M
Total Debt (Recent Filing)$34.52K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume873,809
30 Day Avg. Volume20,747,076
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.56
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$1.00Price Target Upside-15.25% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.41M
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero reported debt materially lowers interest burden and financial distress risk for a development-stage biotech that will likely need additional capital. Low leverage preserves strategic flexibility for financing trials or partnerships without immediate cash flow constraints from debt service.
Phase 2 Manufacturing CompletedCompleting manufacturing for the lead BRTX-100 Phase 2 program is a durable operational milestone that de-risks execution timelines, demonstrates manufacturing capability, and supports the company’s vertically integrated platform—improving prospects for timely data and partnering opportunities.
Management ContinuityMulti-year employment agreements for CEO and CFO provide leadership continuity during pivotal clinical and financing phases, reducing execution risk. Formalized compensation and equity incentives can help retain experienced executives crucial for navigating trials and strategic financing over the medium term.
Bears Say
High Cash BurnSustained and worsening cash burn at nearly $12M TTM creates persistent funding pressure for a company with minimal revenue. This structural cash shortfall implies ongoing reliance on external capital, dilutive financings, or costly debt, increasing execution and survival risk absent material financing or revenue gains.
Tiny, Declining RevenueRevenue is extremely small and falling, leaving the business unable to cover operating costs despite decent gross margins. A shallow and shrinking revenue base means R&D and G&A are funded entirely externally, prolonging dependence on capital markets and raising long-term sustainability concerns.
Costly Loan And Governance ShiftA high-cost revolving loan and lender-appointed directors signal tighter creditor influence and reduce strategic freedom. The 12% rate and board changes increase governance risk and may prioritize creditor protections over shareholder value, while signaling constrained organic liquidity options.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $0.16 and its highest was $1.89 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $10.19M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter, the consensus estimate of -$0.2 by $0.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Overvalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 25,478,170 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.2 in its last earnings report, expectations of -$0.2. Following the earnings report the stock price went down -7.65%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
BRTX Stock 12 Month Forecast
Average Price Target
$1.00
▼(-15.25% Downside)
Technical Analysis
Ownership Overview
1.46% Insiders
0.22% Mutual Funds
0.16% Other Institutional Investors
98.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---